Rotavirus vaccine for preventing diarrhoea

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Soares Weiser, Karla ^a   Goldberg, Elad ^b   Tamimi, Ghandi ^c   Leibovici, Leonard ^b   Pitan, Femi ^d  

^a Enhance Reviews   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c MSF Hebron   (Palestine)

^d CHEVRON NIGERIA LIMITED   (Nigeria)

Author keywords

Adult; Cause of death; diarrhea mortality; *prevention control; virology ; Child; Humans; Randomized controlled trials as topic; Rotavirus infections *prevention control ; Rotavirus vaccines *therapeutic use ; Vaccines, attenuated therapeutic use

Indexed keywords

BICARBONATE; CITRIC ACID; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ORAL POLIOMYELITIS VACCINE; PLACEBO; ROTAVIRUS VACCINE;

ASPHYXIA; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GASTROINTESTINAL REFLUX; HOSPITALIZATION; HUMAN; INTESTINE OBSTRUCTION; INTUSSUSCEPTION; IRRITABILITY; LATEX AGGLUTINATION TEST; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; POLYMERASE CHAIN REACTION; REHYDRATION; RESPIRATORY DISTRESS; REVIEW; ROTAVIRUS; SEPSIS; SERODIAGNOSIS; SIDE EFFECT; SINGLE DRUG DOSE; SUDDEN DEATH; SYSTEMATIC REVIEW; VACCINATION; VIRAL GASTROENTERITIS; VIRUS STRAIN; VOMITING;

EID: 77950171062     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002848.pub2     Document Type: Review

References (163)

1. Anderson 1986 {published data only} Anderson E, Belshe R, Bartram J, Crookshanks-Newman F, Chanock R, Kapikian A. Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. Journal of Infectious Diseases 1986;153(5):823-31.
2. Barnes 1997 {published data only} Barnes G, Lund J, Adams L, Mora A, Mitchell S, Caples A, et al.Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. Journal of Paediatrics and Child Health 1997;33 (4):300-4.
3. Barnes 2002 {published data only} Barnes GL, Lund JS, Mitchell SV, De Bruyn L, Piggford L, Smith AL, et al.Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 2002;20(23-24): 2950-6.
4. Bernstein 1990 {published data only} Bernstein D, Sander D, Smith V, Schiff G, Ward R. Protection from rotavirus reinfection: 2-year prospective study. Journal of Infectious Diseases 1991;164(2):277- 83.
5. * Bernstein D, Smith V, Sander D, Pax K, Schiff G, Ward R. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. Journal of Infectious Diseases 1990;162(5):1055-62.
6. Ward R, Bernstein D. Protection against rotavirus disease after natural rotavirus infection. Journal of Infectious Diseases 1994;169 (4):900-4.
7. Bernstein 1995 {published data only} * Bernstein D, Glass R, Rodgers G, Davidson B, Sack D. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. Journal of the AmericanMedical Association 1995;273(15):1191-6.
8. Ward R, Bernstein D. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine 1995;13(13):1226-32.
9. Bernstein 1998 {published and unpublished data} Bernstein D, Smith V, Sherwood J, Schiff G, Sander D, DeFeudis D, et al.Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998;16(4):381-7.
10. Bernstein 1999 {published and unpublished data} * Bernstein D, Sack D, Rothstein E, Reisinger K, Smith V, O'Sullivan D, et al.Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999;354(9175):287-90.
11. Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. Journal of Infectious Diseases 2002;186(10):1487- 9.
12. Bresee 2001 {published data only} Bresee JS, El Arifeen S, Azim T, Chakraborty J, Mounts AW, Podder G, et al.Safety and immunogenicity of tetravalent rhesusbased rotavirus vaccine in Bangladesh. Pediatric Infectious Disease Journal 2001;20(12):1136-43.
13. Christy 1988 {published and unpublished data} Christy C, Madore H, Pichichero M, Gala C, Pincus P, Vosefski D, et al.Field trial of rhesus rotavirus vaccine in infants. Pediatric Infectious Disease Journal 1988;7(9):645-50.
14. Christy 1993 {published and unpublished data} Christy C, Offit P, Clark H, Treanor J. Evaluation of a bovinehuman rotavirus reassortant vaccine in infants. Journal of Infectious Diseases 1993;168(6): 1598-9.
15. Clark 1988 {published data only} Clark H, Borian F, Bell L, Modesto K, Gouvea V, Plotkin S. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. Journal of Infectious Diseases 1988;158(3):570-87.
16. Clark 1990 {published data only} Clark H, Borian F, Plotkin S. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. Journal of Infectious Diseases 1990;161(6): 1099-104.
17. Clark 1995 {published data only} * Clark H, Offit P, Ellis R, Eiden J, Krah D, Shaw A, et al.The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Journal of Infectious Diseases 1996; 174 Suppl 1:73-80.
18. Clark H, White C, Offit P, Stinson D, Eiden J, Weaver S, et al.Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine [abstract]. Pediatric Research 1995;37:172A.
19. Clements-Mann 1999 {published data only} Clements-Mann M, Makhene M, Mrukowicz J, Wright P, Hoshino Y, Midthun K, et al.Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specifiity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine 1999;17(20-21):2715-25.
20. Dagan 1992 {published data only} * Dagan R, Kassis I, Sarov B, Midthun K, Davidson B, Vesikari T, Sarovi I. Safety and immunogenicity of oral tetravalent humanrhesus reassortant rotavirus vaccine in neonates. Pediatric Infectious Diseases Journal 1992;11(12):991-6.
21. Dagan R, Kassis I, Sarov B, Midthun K, Sarov I. Safety and immunogenicity of oral rhesus rotavirus tetravalent vaccine (ORRTV) in neonates. Pediatric Research 1991;29:117.
22. De Mol 1986 {published data only} De Mol P, Zissis G, Butzler J, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986;2(8498):108.
23. Dennehy 1996 {published and unpublished data} Dennehy PH, Rodgers GC Jr, Ward RL, Markwick AJ, Zito ET. Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group. Pediatric Infectious Disease Journal 1996;15(11):1012-8.
24. Eichelberger 2002 {published data only} Eichelberger M, Sperber E, Wagner M, Hoshino Y, Dudas R, Hodgins V, et al.Clinical evaluation of a single oral dose of humanbovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2). Journal of Medical Virology 2002;66(3):407-16.
25. Escobar 1988 {published data only} Escobar Castro H, Perdomo Giraldi M, Tamariz-Martel Moreno A, Suarez Cortina L. Oral vaccination with live attenuated rotavirus [Vacunacion oral con rotavirus vivo atenuado]. Anales Espanoles de Pediatria 1988;28(6):527-9.
26. Flores 1988 {published data only} * Flores J, Daoud G, Daoud N, Puig M, Martinez M, Perez-Schael I, et al.Reactogenicity and antigenicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in Venezuela. Pediatric Infectious Disease Journal 1988;7(11):776-80.
27. Kapikian AZ, Flores J, Midthun K, Hoshino Y, Green KY, Gorziglia M, et al.Strategies for the development of a rotavirus vaccine against infantile diarrhea with an update on clinical trials of rotavirus vaccines. Advances in Experimental Medicine and Biology 1989;257:67-89.
28. Flores 1989 {published data only} Flores J, Perez-Schael I, Blanco M, Vilar M, Garcia D, Perez M, et al.Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants. Journal of Clinical Microbiology 1989;27(3):512-8.
29. Flores 1990 {published data only} Flores J, Perez-Schael I, Blanco M, White L, Garcia D, Vilar M, et al.Comparison of reactogenicity and antigenicity of M37 rotavirus vaccine and rhesus-rotavirus-based quadrivalent vaccine. Lancet 1990;336(8711):330-4.
30. Flores 1993 {published data only} Flores J, Perez-Schael I, Blanco M, Rojas AM, Alfonzo E, Crespo I, et al.Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine. Journal of Clinical Microbiology 1993;31(9):2439-45.
31. Georges-Courbot 1991 {published and unpublished data} Georges-Courbot MC, Monges J, Siopathis MR, Roungou JB, Gresenguet G, Bellec L, et al.Evaluation of the efficacy of a lowpassage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Research in Virology 1991;142(5):405-11.
32. Gothefors 1989 {published and unpublished data} Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian A, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. Journal of Infectious Diseases 1989;159(4):753-7.
33. Hanlon 1987 {published data only} Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-KingM, et al.Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987;1(8546):1342-5.
34. Ho 1989 {published and unpublished data} Ho MS, Floyd RL, Glass RI, Pallansch MA, Jones B, Hamby B, et al.Simultaneous administration of rhesus rotavirus vaccine and oral poliovirus vaccine: immunogenicity and reactogenicity. Pediatric Infectios Disease Journal 1989;8(10): 692-6.
35. Ing 1991 {published and unpublished data} Ing DJ, Glass RI, Woods PA, Simonetti M, Pallansch MA,Wilcox WD, et al.Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. American Journal of Diseases of Children 1991;145(8):892- 7.
36. Joensuu 1997 {published data only} * Joensuu J, Koskenniemi E, Pang X, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350(9086):1205-9.
37. Joensuu J, Koskenniemi E, Vesikari T. Prolonged efficacy of rhesushuman reassortant rotavirus vaccine. Pediatric Infectious Disease Journal 1998;17(5):427-9.
38. Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatric Infectious Disease Journal 1998;17(4):334-40.
39. Takala A, Koskenniemi E, Joensuu J, Makela M, Vesikari T. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clinical Infectious Diseases 1998;27(2): 272-82.
40. Vesikari T. New vaccine is effective against rotavirus-induced diarrhea. American Family Physician 1997;55(4):1337.
41. Lanata 1989 {published and unpublished data} Lanata C, Black R, del-Aguila R, Gil A, Verastegui H, Gerna G, et al.Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. Journal of Infectious Diseases 1989;159(3):452-9.
42. Lanata 1996a {published and unpublished data} Lanata C, Black R, Flores J, Lazo F, Butron B, Linhares A, et al.Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996;14 (3):237-43.
43. Lanata 1996b {published and unpublished data} Lanata CF, Black RE, Flores J, Lazo F, Butron B, Linares A, et al.Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. Journal of Infectious Diseases 1996;174(2):268-75.
44. Linhares 1996 {published and unpublished data} * Linhares AC, Gabbay YB, Mascarenhas JD, de Freitas RB, Oliveira CS, Bellesi N, et al.Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bulletin of the World Health Organization 1996;74(5): 491-500.
45. Linhares AC, Lanata CF, Hausdorff WP, Gabbay Y, Black RE. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea. Pediatric Infectious Disease Journal 1999;18 (11):1001-6.
46. Madore 1992 {published data only} Madore H, Christy C, Pichichero M, Long C, Pincus P, Vosefsky D, et al.Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups. Journal of Infectious Diseases 1992;166(2):235-43.
47. Maldonado 1986 {published and unpublished data} Maldonado Y, Hestvik L, Wilson M, Townsend T, O'Hare J, Wee S, et al.Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants. Journal of Pediatrics 1986;109(6): 931-5.
48. Mutz 1989 {published and unpublished data} Mutz I, Krainer F, Deutsch J, Kunz C, Teuwen D. A trial of RIT-4237 rotavirus vaccine in 1-month-old infants. European Journal of Pediatrics 1989;148(7): 634-5.
49. Perez-Schael 1990a {published and unpublished data} Flores J, Perez-Schael I, Gonzalez M, Garcia D, Perez M, Daoud N, et al.Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987; Vol. 1, issue 8538:882-4.
50. * Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, et al.Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. Journal of Medical Virology 1990;30(3):219-29.
51. Perez-Schael I, Garcia D, White L, Blanco M, Gonzalez R, Urbina G, et al.Field tests for anti-rotavirus vaccine carried out in Venezuela [Pruebas de campo de una vacuna anti-rotavirus realizadas en Venezuela (1985-1989)]. Archivos Venezolanos de Puericultura y Pediatria 1990;53 Suppl(2):29-36.
52. Perez-Schael I, Gonzalez M, Daoud N, Perez M, Soto I, Garcia D, et al.Reactogenicity and antigenicity of the rhesus rotavirus vaccine in Venezuelan children. Journal of Infectious Diseases 1987;155(2): 334-8.
53. Perez-Schael 1990c {published data only} Perez-Schael I, Blanco M, Vilar M, Garcia D, White L, Gonzalez R, et al.Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. Journal of Clinical Microbiology 1990;28(3): 553-8.
54. Perez-Schael 1994 {published and unpublished data} Perez-Schael I, Blanco M, Garcia D, White L, Alfonzo E, Crespo I, et al.Evaluation of the antigenicity and reactogenicity of varying formulations of the rhesus rotavirus-based quadrivalent and the M37 rotavirus vaccine candidates. Journal of Medical Virology 1994;42(4):330-7.
55. Perez-Schael 1997 {published and unpublished data} Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzalez R, et al.Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. New England Journal of Medicine 1997;337(17):1181-7.
56. Perez-Schael 2002 {unpublished data only} * Perez-Schael I, Salinas B, Linhares A, Guerrero M, Ruiz-Palacios G, Clemens S, Jacquet J, De Vos B. Protective Efficacy Of An Oral Human Rotavirus (HRV) Vaccine In Latin American Infants. 42nd Annual ICAAC. San Diego, California, 2002:18, LB-23.
57. Pichichero 1990 {published data only} Pichichero ME, Losonsky GA, Rennels MB, Disney FA, Green JL, Francis AB, et al.Effect of dose and a comparison of measures of vaccine take for oral rhesus rotavirus vaccine. The Maryland Clinical Studies Group. Pediatric Infectious Disease Journal 1990;9 (5):339-44.
58. Pichichero 1993 {published data only} Pichichero ME, Losonsky GA. Asymptomatic infections due to wild-type rotavirus may prime for a heterotypic response to vaccination with rhesus rotavirus. Clinical Infectious Diseases 1993; 16(1):86-92.
59. * Pichichero ME, Marsocci SM, Francis AB, Green JL, Disney FA, Rennels MB, et al.A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants. Vaccine 1993;11 (7):747-53.
60. Rennels 1987 {published data only} Losonsky GA, Rennels MB, Kapikian AZ, Midthun K, Ferra PJ, Fortier DN, et al.Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infants. Pediatric Infectious Disease 1986;5(1):25-9.
61. Rennels MB, Losonsky GA, Levine MM, Kapikian AZ. Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children. Pediatric Infectious Disease 1986;5(5): 587-8.
62. * Rennels MB, Losonsky GA, Shindledecker CL, Hughes TP, Kapikian AZ, Levine MM. Immunogenicity and reactogenicity of lowered doses of rhesus rotavirus vaccine strain MMU 18006 in young children. Pediatric Infectious Disease Journal 1987;6(3): 260-4.
63. Rennels 1990 {published data only} Rennels MB, Losonsky GA, Young AE, Shindledecker CL, Kapikian AZ, Levine MM. An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group. American Journal of Diseases of Children 1990;144(5):601-4.
64. Rennels 1995 {published data only} Rennels MB, Wasserman SS, Glass RI, Keane VA. Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. US Rotavirus Vaccine Efficacy Group. Pediatrics 1995;96(6):1132-6.
65. Rennels 1996 {published data only} Dennehy PH, Rodgers GC Jr, Ward RL, Markwick AJ, Mack M, Zito ET. Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. US Rhesus Rotavirus Vaccine Study Group. Pediatric Infectious Disease Journal 1996;15(11):1012-8.
66. Griffiths RI, Anderson GF, Powe NR, Oliveras E, Herbert RJ, Grant CC, et al.Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial. Archives of Pediatrics & Adolescent Medicine 1995;149(4):407-14.
67. * Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, et al.Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996;97(1):7-13.
68. Rennels MB, Ward RL, Mack ME, Zito ET. Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group. Journal of Infectious Diseases 1996;173(2):306-13.
69. Ruuska 1990 {published data only} * Ruuska T, Vesikari T, Delem A, Andre F, Beards G, Flewett T. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scandinavian Journal of Infectious Diseases 1990;22(3):269-78.
70. Vesikari T, Ruuska T, Delem A, Andre F. Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatric Infectious Disease Journal 1987;6(2):164-9.
71. Santosham 1991a {published data only} Santosham M, Letson GW, Wolff M, Reid R, Gahagan S, Adams R, et al.A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. Journal of Infectious Diseases 1991;163(3):483-7.
72. Santosham 1991b {published data only} Santosham M, Letson GW, Wolff M, Reid R, Gahagan S, Adams R, et al.A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. Journal of Infectious Diseases 1991;163(3):483-7.
73. Santosham 1997 {published and unpublished data} Santosham M, Moulton LH, Reid R, Croll J, Weatherholt R, Ward R, et al.Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. Journal of Pediatrics 1997;131(4):632-8.
74. Senturia 1987 {published and unpublished data} Senturia YD, Peckham CS, Cordery M, Chrystie IA, Banatvala JE, Andre FE. Live attenuated oral rotavirus vaccine. Lancet 1987;2 (8567):1091-2.
75. Treanor 1995 {published data only} Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, et al.The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Journal of Infectious Diseases 1996; 174 Suppl 1:73-80.
76. * Treanor JJ, Clark HF, Pichichero M, Christy C, Gouvea V, Shrager D, et al.Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatric Infectious Disease Journal 1995;14(4):301-7.
77. Vesikari 1984 {published data only} Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE. Increased "take" rate of oral rotavirus vaccine in infants after milk feeding. Lancet 1984;2(8404):700.
78. * Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1(8384): 977-81.
79. Vesikari 1985a {published data only} Vesikari T. Rotavirus infections and their prevention by vaccination. Antiviral Research 1985;Suppl 1:293-300.
80. * Vesikari T, Isolauri E, Delem A, d'Hondt E, Andre FE, Beards GM, et al.Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. Journal of Pediatrics 1985;107(2):189-94.
81. Vesikari T, Isoulari E, Andre F. Protection of children for two years against rotavirus diarrhea by RIT 4237 (NCDV) rotavirus vaccine. In: Holmgren J, Linderg A, Mollby R editor(s). Development of vaccines and drugs against diarrhea. 11th Nobel Conference, Stockolm 1985. Lund, Sweden: Studentlitteratur, 1986:189-94.
82. Vesikari 1986a {published data only} Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. Journal of Infectious Diseases 1986;153 (5):832-9.
83. Vesikari 1987b {published data only} Vesikari T, Ruuska T, Delem A, Andre FE. Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatric Infectious Disease Journal 1987;6(2):164-9.
84. Vesikari 1990 {published data only} Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. American Journal of Diseases of Children 1990;144(3):285-9.
85. Vesikari 1991a {published data only} Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatrica Scandinavica 1991;80(2):173-80.
86. Vesikari 1991b {published data only} Vesikari T, Ruuska T, Koivu HP, Green KY, Flores J, Kapikian AZ. Evaluation of the M37 human rotavirus vaccine in 2- to 6-monthold infants. Pediatric Infectious Disease Journal 1991;10(12):912-7.
87. Vesikari 1991c {published data only} Vesikari T, Varis T, Green K, Flores J, Kapikian AZ. Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity. Vaccine 1991;9(5): 334-9.
88. Vesikari 1992 {published data only} Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesushuman reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatric Infectious Disease Journal 1992; 11(7):535-42.
89. Vesikari 1999 {published data only} Vesikari T, Joensuu J, Baer M, Kayhty H, Olander RM, Sormunen H, et al.Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines. Acta Paediatrica 1999;88(5):513-20.
90. Wright 1987 {published data only} Wright PF, Tajima T, Thompson J, Kokubun K, Kapikian A, Karzon DT. Candidate rotavirus vaccine (rhesus rotavirus strain) in children: an evaluation. Pediatrics 1987;80(4):473-80.
91. Ceyhan 1993 {published data only} Ceyhan M, Kanra G, Secmeer G, Midthun K, Davidson BL, Zito ET, et al.Take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants. Acta Paediatrica 1993;82(3):223-7.
92. Christy 1986 {published data only} Christy C, Madore HP, Treaner JJ, Pray K, Kapikian AZ, Chanock RM, et al.Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine. Journal of Infectious Diseases 1986;154 (6):1045-7.
93. Clements-Mann 2001 {published data only} Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, et al.Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 2001;19 (32):4676-84.
94. Friedman 1993 {published data only} Friedman MG, Segal B, Zedaka R, Sarov B, Margalith M, Bishop R, et al.Serum and salivary responses to oral tetravalent reassortant rotavirus vaccine in newborns. Clinical and Experimental Immunology 1993;92(2):194-9.
95. Giammanco 1988 {published data only} Giammanco G, De Grandi V, Lupo L, Mistretta A, Pignato S, Teuween D, et al.Interference of oral poliovirus vaccine on RIT 4237 oral rotavirus vaccine. European Journal of Epidemiology 1988; 4(1):121-3.
96. Halsey 1988 {published data only} * Halsey NA, Anderson EL, Sears SD, Steinhoff M, Wilson M, Belshe RB, et al.Human-rhesus reassortant rotavirus vaccines: safety and immunogenicity in adults, infants, and children. Journal of Infectious Diseases 1988;158(6):1261-7.
97. Midthun K, Halsey NA, Jett-Goheen M, Clements ML, Steinhoff M, King JC, et al.Safety and immunogenicity of human rotavirus vaccine strain M37 in adults, children, and infants. Journal of Infectious Diseases 1991;164(4):792-6.
98. Isolauri 1995 {published data only} Isolauri, E, Joensuu, J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995;13(3):310-2.
99. Jalil 1991 {published data only} Jalil F, Zaman S, Carlsson B, Glass RI, Kapikian AZ, Mellander L, et al.Immunogenicity and reactogenicity of rhesus rotavirus vaccine given in combination with oral or inactivated poliovirus vaccines and diphteria-tetanus-pertussis vaccine. Transactions of the Royal Society of Tropical Medicine and Hygiene 1991;85(2):292-6.
100. Jin 1996 {published data only} Jin Q, Ward RL, Knowlton DR, Gabbay YB, Linhares AC, Rappaport R, et al.Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses. Archives of Virology 1996;141(11):2057-76.
101. Kobayashi 1993 {published data only} Kobayashi M, Araki K, Thompson J, Tollefson SJ, Wright PF. Sequential administration of two human-rhesus rotavirus reassortant strains of VP7 serotype 1 and 2 specificity to infants and young children. Journal of Infectious Diseases 1993;167(3):748-52.
102. Kobayashi 1994 {published data only} Kobayashi M, Thompson J, Tollefson SJ, Reed GW, Wright PF. Tetravalent rhesus rotavirus vaccine in young infants. Journal of Infectious Diseases 1994;170(5):1260-3.
103. Losonsky 1988 {published data only} Losonsky GA, Rennels MB, Lim Y, Krall G, Kapikian AZ, Levine MM. Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006. Pediatric Infectious Disease 1988;7(6): 388-93.
104. Markwick 1998 {published data only} Markwick AJ, Rennels MB, Zito ET, Wade MS, Mack ME. Oral tetravalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine. US Rhesus Rotavirus Vaccine Study Group. Pediatric Infectious Disease Journal 1998;17(10):913-8.
105. Midthun 1989 {published data only} Midthun K, Pang LZ, Flores J, Kapikian AZ. Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates. Journal of Clinical Microbiology 1989;27(12): 2799-804.
106. Padilla 1992 {published data only} Padilla-Noriega L, Fiore L, Rennels M, Losonsky G, Mackow E, Greenberg H. Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus. Journal of Clinical Microbiology 1992;30(6):1392-7.
107. Pang 1999a {published data only} Pang XL, Joensuu J, Hoshino Y, Kapikian AZ, Vesikari T. Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis. Journal of Clinical Virology 1999;13(1-2):9-16.
108. Pang 1999b {published data only} Pang XL, Vesikari T. Human astrovirus-associated gastroenteritis in children under 2 years of age followed prospectively during a rotavirus vaccine trial. Acta Paediatrica 1999;88(5):532-6.
109. Pang 1999c {published data only} Pang XL, Koskenniemi E, Joensuu J, Vesikari T. Effect of rhesus rotavirus vaccine on enteric adenovirus - associated diarrhea in children. Journal of Pediatric Gastroenterology and Nutrition 1999; 29(3):366-9.
110. Pang 1999d {published data only} Pang XL, Joensuu J, Vesikari T. Human calicivirus-associated sporadic gastroenteritis in Finnish children less than two years of age followed prospectively during a rotavirus vaccine trial. Pediatric Infectious Disease Journal 1999;18(5): 420-6.
111. Pickering 1995 {published data only} Pickering LK, Morrow AL, Herrera I, O'Ryan M, Estes MK, Guilliams SE, et al.Effect of maternal rotavirus immunization on milk and serum antibody titers. Journal of Infectious Diseases 1995; 172(3):723-8.
112. Simasathien 1994 {published data only} Migasena S, Simasathien S, Samakoses R, Pitisuttitham P, Sangaroon P, van Steenis G, et al.Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine 1995;13(2):168-74.
113. * Simasathien S, Migasena S, Samakoses R, Pitisuttitham P, Sangaroon P, Aree C, et al.Vaccination of Thai infants with rhesushuman reassortant tetravalent oral rotavirus vaccine. Pediatric Infectious Disease Journal 1994;13(7):590-6.
114. Tajima 1990 {published data only} Tajima T, Thompson J, Wright PF, Kondo Y, Tollefson SJ, King J, et al.Evaluation of a reassortant rhesus rotavirus vaccine in young children. Vaccine 1990;8(1):70- 4.
115. Ukae 1994 {published data only} Ukae S, Nakata S, Adachi N, Kogawa K, Chiba S. Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus. Vaccine 1994;12(10): 933-9.
116. Vesikari 1983 {published data only} Vesikari T, Isolauri E, Delem A, D'Hondt E, Andre FE, Zissis G. Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet 1983;2(8354):807-11.
117. Vesikari 1985b {published data only} Vesikari T, Ruuska T, Bogaerts H, Delem A, Andre F. Doseresponse study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Pediatric Infectious Disease 1985;4(6):622-5.
118. Vesikari 1986b {published data only} Vesikari T, Ruuska T, Delem A, Andre FE. Oral rotavirus vaccination in breast- and bottle-fed infants aged 6 to 12 months. Acta Paediatrica Scandinavica 1986;75(4):573-8.
119. Vesikari 1987a {published data only} Vesikari T, Rautanen T, Isolauri E, Delem A, Andre FE. Immunogenicity and safety of a low passage level bovine rotavirus candidate vaccine RIT 4256 in human adults and young infants. Vaccine 1987;5(2):105-8.
120. Vodopija 1986 {published data only} Vodopija I, Baklaic Z, Vlatkovic R, Bogaerts H, Delem A, Andre FE. Combined vaccination with live oral polio vaccine and the bovine rotavirus RIT 4237 strain. Vaccine 1986;4(4):233-6.
121. Wright 1991 {published and unpublished data} Wright PF, King J, Araki K, Kondo Y, Thompson J, Tollefson SJ, et al.Simultaneous administration of two human-rhesus rotavirus reassortant strains of VP7 serotype 1 and 2 specificity to infants and young children. Journal of Infectious Diseases 1991;164(2):271-6.
122. Zoppi 1986 {published data only} Zoppi G, Ferrarini G, Rigolin F, Bogaerts H, Andre FE. Response to RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Helvetica Paediatrica Acta 1986;41(3):203-8.
123. Zoppi 1989 {published data only} Zoppi G, Mantovanelli F, Pittschieler K, Delem A, Teuwen DE. Response to RIT 4237 oral rotavirus vaccine in human milk, adapted-and soy-formula fed infants. Acta Paediatrica Scandinavica 1989;78(5):759-62.
124. Seth 2000 {published data only} Seth R, Mohan A. Efficacy of monovalent human rotavirus vaccine 89-12 in infants. National Medical Journal of India 2000;13(5): 253-4.
125. Vesikari 2002 {published data only} * Vesikari T, Karvonen A, Espo M, Korhonen T, Delem A, de Vos B. Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 2002.
126. AP 1998 American Academy of Pediatrics. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 1998;102(6): 1483-91.
127. Altman 2002 Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Medical Research Methodology 2002; 2(1):3.
128. Bresee 1999 Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999;17(18): 2207-22.
129. Cale 2002 Cale CM, Klein NJ. The link between rotavirus vaccination and intussusception: implications for vaccine strategies. Gut 2002;50 (1):11-2.
130. CDC 1999 Center for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. Journal of AmericanMedical Association 1999;282(6):520- 1.
131. CDC 1999a Center for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports 1999;48 (RR-2):1-20.
132. Clarke 2003 Clarke M, Oxman A, editors. Optimal search strategy for RCTs. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]; Appendix C. In: The Cochrane Library [database on CDROM]. The Cochrane Collaboration. Chichester: Wiley; 2003, issue 3.
133. Cunliffe 2002 Cunliffe NA, Bresee JS, Hart CA. Rotavirus vaccines: development, current issues and future prospects. Journal of Infection 2002;45(1): 1-9.
134. Flores 1987 Flores J, Perez-Schael I, Gonzalez M, Garcia D, Perez M, Daoud N, et al.Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987;1(8538):882- 4.
135. Glass 1999 Glass RI, Bresee JS, Parashar UD, Holman RC, Gentsch JR. First rotavirus vaccine licensed: is there really a need?. Acta Paediatrica. Supplement 1999;88(426):2-8.
136. Griffiths 1995 Griffiths RI, Anderson GF, Powe NR, Oliveras E, Herbert RJ, Grant CC, et al.Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial. Archives of Pediatrics & Adolescent Medicine 1995;149(4):407-14.
137. Henchal 1996 Henchal LS, Midthun K, Goldenthal KL. Selected regulatory and scientific topics for candidate rotavirus vaccine development. Journal of Infectious Diseases 1996;174 Suppl 1:112-7.
138. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency is preferable to testing for heterogeneity in metaanalysis. BMJ 2003;327:557-60.
139. Jacobson 2001 Jacobson RM, Adegbenro A, Pankratz VS, Poland GA. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 2001;19(17-19): 2428-33.
140. Jones 2001 Jones T. Rotavirus vaccine AVANT/GlaxoSmithKline. Current Opinion in Investigational Drugs 2001;2(7):893-5.
141. Josefson 1997 Josefson D. Rotavirus vaccine is effective in developing countries. BMJ 1997;315:1111-6.
142. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in healthcare: Assessing the quality of controlled trials. BMJ 2001;323(7303): 42-6.
143. Matson 1990 Matson DO, Estes MK. Impact of rotavirus infection at a large at a large pediatric hospital. Journal of Infectious Diseases 1990;162(3): 598-604.
144. Merck 1999 Merck, Co. Rotavirus W179-9 vaccine. Drugs in R&D 1999;2(3): 220-1.
145. MMWR 1999a MMWR. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. Morbidity and mortality weekly report 1999;48(27):577-81.
146. MMWR 1999b MMWR. Withdrawal of rotavirus vaccine recommendation. Morbidity and mortality weekly report 1999;48(43):1007.
147. Murphy 2001 Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, et al.Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine 2001;344(8): 564-72.
148. Murphy 2002 Murphy TV, Gargiullo PM, Wharton M. More on rotavirus vaccination and intussusception. New England Journal of Medicine 2002;346(3):211-2.
149. Newcombe 1998 Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in Medicine 1998;17(8):873-90.
150. Niu 2001 Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001;19(32): 4627-34.
151. Perez-Schael 1990b Perez-Schael I, Blanco M, Vilar M, Garcia D, White L, Gonzalez R, et al.Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. Journal of Clinical Microbiology 1990;28(3): 553-8.
152. Perez-Schael 2001 Perez-Schael I. Future of research into rotavirus vaccine. Developing countries must apply mathematics to take their own decisions. BMJ 2001;322(7278):106-7.
153. Peter 2002 Peter G, Myers MG, National Vaccine Advisory Committee, National Vaccine Program Office. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 2002;110(6):1-6.
154. Rennels 1998 Rennels MB, Parashar UD, Holman RC, Le CT, Chang HG, Glass RI. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatric Infectious Disease Journal 1998;17(10):924-5.
155. Tucker 1998 Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Journal of American Medical Association 1998;279(17):1371-6.
156. Verstraeten 2001 Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen RT, Vaccine Adverse Event Reporting System Team. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. American Journal of Epidemiology 2001;154(11):1006-12.
157. Vesikari 1997 Vesikari T. Rotavirus vaccines against diarrhoeal disease. Lancet 1997;350(9090):1538-41.
158. Weijer 2000 Weijer C. The future of research into rotavirus vaccine. BMJ 2000; 321(7260):525-6.
159. WHO 1995 World Health Organization. Diarrhoeal Disease Control Programme. The treatment of diarrhoea: a manual for physicians and other senior health workers. 3rd Edition. Geneva: World Health Organization, 1995.
160. WHO 2003 World Health Organization. Child and Adolescent Health and Development. Proportional mortality among children under fives, regions [2001]. http://www.who.int/child-adolescent-health/ OVERVIEW/CHILD?HEALTH/map? 01?regions.jpg (accessed 23 October 2003).
161. WHO/UNICEF 2002 World Health Organization. Dept. of Vaccines and Biologicals. State of the world's vaccines and immunization. Geneva: World Health Organization, 2002.
162. World Bank 2003 The World Bank Group. Data & statistics: country group. http://www.worldbank.org/data/countryclass/classgroups.htm (accessed 23 October 2003).
163. Zanardi 2001 Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics 2001;107(6): E97.